@article{78b09bd1aa924cfba6732be80d94e913,
title = "Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression",
author = "Reinen, {Jenna M.} and Whitton, {Alexis E.} and Pizzagalli, {Diego A.} and Mark Slifstein and Anissa Abi-Dargham and McGrath, {Patrick J.} and Iosifescu, {Dan V.} and Schneier, {Franklin R.}",
note = "Funding Information: Dr. Whitton was partially supported by R01 MH1099322 and by grant number APP1110773 from the National Health and Medical Research Council. Funding Information: This study was supported by Award Number R01 MH1099322 (awarded to Dr. Schneier) from the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or National Institutes of Health. Dr. Pizzagalli was partially supported by R37 MH068376 and R01 MH101521. Dr. Whitton was partially supported by R01 MH1099322 and by grant number APP1110773 from the National Health and Medical Research Council. None of the funding sources provided any further role in the study design, collection, analysis, interpretation of data, writing of the report, or in the decision to submit the paper for publication. Preparing and writing manuscript: JMR, AEW, DAP, FRS. Designed the study and wrote clinical protocol: FRS, DAP, AAD. Designed imaging task: JMR. Analyzed the data: JMR, AEW. Oversaw clinical aspects of the study: FRS. Contributed to editing, scientific feedback, and final version of the paper: JMR, AEW, DAP, MS, AAD, PJM, DI, FRS. The authors would like to thank Jochen Weber (Columbia University) for consulting on neuroimaging analyses. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, and Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. With the exception of NIMH, no funding from these entities was used to support the current work. Dr Slifstein has provided consultation for Curasen Therapeutics and Neurocrine and has stock options in Storm Biosciences Inc. Dr. Abi- Dargham received consulting fees and/or honoraria from Sunovion, Otsuka, Merck, and Neurocrine. She holds stock options in Systems 1 Bio and in Terran Biosciences. In the past 5 years, Dr. Iosifescu was a consultant for Alkermes, Axsome, Allergan, Biogen, Centers of Psychiatric Excellence, MyndAnalytics, Jazz Pharmaceuticals, Lundbeck, Otsuka, Precision Neuroscience, Sage, and Sunovion; he has received research support (through his academic institution) from Alkermes, Astra Zeneca, Brainsway, Litecure, Neosync, Roche, and Shire. Dr. Schneier has received research support from Forest Laboratories, Otsuka Pharmaceuticals, Compass Pathways, and consulting fees from Feelmore Rx. No other disclosures were reported. Funding Information: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, and Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. With the exception of NIMH, no funding from these entities was used to support the current work. Dr Slifstein has provided consultation for Curasen Therapeutics and Neurocrine and has stock options in Storm Biosciences Inc. Dr. Abi- Dargham received consulting fees and/or honoraria from Sunovion, Otsuka, Merck, and Neurocrine. She holds stock options in Systems 1 Bio and in Terran Biosciences. In the past 5 years, Dr. Iosifescu was a consultant for Alkermes, Axsome, Allergan, Biogen, Centers of Psychiatric Excellence, MyndAnalytics, Jazz Pharmaceuticals, Lundbeck, Otsuka, Precision Neuroscience, Sage, and Sunovion; he has received research support (through his academic institution) from Alkermes, Astra Zeneca, Brainsway, Litecure, Neosync, Roche, and Shire. Dr. Schneier has received research support from Forest Laboratories, Otsuka Pharmaceuticals, Compass Pathways, and consulting fees from Feelmore Rx. No other disclosures were reported. Funding Information: This study was supported by Award Number R01 MH1099322 (awarded to Dr. Schneier) from the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or National Institutes of Health. Publisher Copyright: {\textcopyright} 2021 Elsevier B.V. and ECNP",
year = "2021",
month = dec,
doi = "10.1016/j.euroneuro.2021.08.002",
language = "English",
volume = "53",
pages = "89--100",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
}
